Substance
ID:73058
Names and Identifiers
Synonyms
EntinostatMS-27-275MS-275SNDX-275
IUPAC Traditional name
entinostat
IUPAC name
pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
Registration numbers
CAS Number
Properties
Safety Information
Storage Condition
-20°C
Physical Property
Solubility
DMSO
Pharmacology Properties
Target
HDAC
Product Information
Salt Data
Free Base
Molecule Details
Research Area
Description
Cancer
Biological Activity
Description
MS-275 is an HDAC inhibitor of HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.
Targets
HDAC1
IC50
0.51 μM
In Vitro
MS-275 shows inhibitory to HDACs by 2′-amino group. MS-275 induces accumulation of p21 WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]
In Vivo
MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]
Clinical Trials
MS-275 is currently in Phase I/II clinical trials in recurrent advanced non-small cell lung cancer, combining with 5-azacytidine.
Features
Protocol
Kinase Assay [6]
Standard HDAC Assays
Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Assay [2]
Cell Lines
A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
Concentrations
~ 10 μM
Incubation Time
3 days
Methods
Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.
Animal Study [1]
Animal Models
A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
Formulation
Dissolved with 0.05 N HCl, 0.1% Tween 80
Doses
12.3, 24.5 and 49 mg/kg
Administration
Administered orally once daily 5 days per week for 4 weeks
Molecular Spectra
No Data Available
Click here to submit data
References
• Sugawara T, et al. 95th AACR, Orlando, 2004, Abst#2451
• Zhang ZY, et al. Neurosci, 2010, 169, 370-377.
• Saito A, et al. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597.
• Kato Y, Clin Cancer Res, 2007, 13(15), 4538-4546.
• Wegener D, et al. Chem Biol, 2003, 10(1), 61-68.
• Rosato RR, et al. Cancer Res, 2003, 63(13), 3637-3645.